IL17A and COVID-19: A previous set of cytokine quantification assays performed in a pilot screening of plasma soluble proteins with COVID-19 and CAP patients revealed differences in the plasma levels of IL-11, IL-17 and the tissue inhibitor of metalloproteinases 2 (TIMP-2) (Supplementary Figure 3).